Loading
A phase 3 trial testing ADI-PEG20 in hepatocellular carcinoma, now recruiting.
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT05317819, led by Polaris, and recruiting on the registry. Official title: A Randomised, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma. Planned enrolment is 300 participants (estimated). The study started in 2022-03-14 and primary completion is expected in 2028-09. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/